# Guerbet clinical trials: 42 on ClinicalTrials.gov (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 42 trials with Guerbet as lead sponsor, 2 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Guerbet: 42 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/guerbet

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 42
- Recruiting or not yet: 2
- Read on: November 19, 2026

## Trials

The 25 newest of 42, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| January 16, 2026 | NCT07348640 | Evaluation of the Efficacy and Safety of Magnetic Resonance Angiography (MRA) Using Gadopiclenol Compared to Gadoterate Meglumine in the... | Guerbet | Phase 3 | Recruiting | Steno-occlusive Disease | 315 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07348640) |
| September 28, 2023 | NCT06057168 | Performance of Elucirem in DSC-MRI Perfusion of Brain Gliomas | Guerbet | Phase 3 | Completed | Brain Tumor, Primary, Brain Tumor, Recurrent | 138 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06057168) |
| August 24, 2023 | NCT06010173 | Evaluation of Gadopiclenol for Magnetic Resonance Imaging (MRI) in Japanese Adults and Children | Guerbet | Phase 3 | Completed | Lesion in Body Region, CNS Lesion | 240 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06010173) |
| October 21, 2022 | NCT05590884 | Gadopiclenol Pharmacokinetics, Safety and Efficacy in Children \< 2 Years of Age | Guerbet | Phase 2 | Completed | Central Nervous System Diseases, Pediatric Disorder, Body Indication | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05590884) |
| September 13, 2022 | NCT05537779 | Safety and Performance of Optivantage Multi-use When Injecting Contrast Media for Contrast Enhanced CT Examination | Guerbet | Observational | Unknown | Patient Participation | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05537779) |
| April 7, 2022 | NCT05316077 | Safety and Performance of Vectorio® in Conventional Trans-Arterial Chemo-Embolization (cTACE): A Post-Market Clinical Follow-up | Guerbet | Observational | Unknown | Oncology | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05316077) |
| May 28, 2021 | NCT04906005 | Pharmacokinetics and Safety of Gadopiclenol in Japanese Healthy Volunteers | Guerbet | Phase 1 | Completed | Pharmacokinetics | 27 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04906005) |
| May 4, 2020 | NCT04373564 | Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination... | Guerbet | Phase 4 | Recruiting | Motor Function, Cognitive Function, Contrast Media | 2,076 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04373564) |
| June 24, 2019 | NCT03996447 | Efficacy and Safety of Gadopiclenol for Central Nervous System (CNS) Magnetic Resonance Imaging (MRI) | Guerbet | Phase 3 | Completed | CNS Lesion, Blood Brain Barrier Defect | 260 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03996447) |
| June 14, 2019 | NCT03986138 | Efficacy and Safety of Gadopiclenol for Body Magnetic Resonance Imaging (MRI) | Guerbet | Phase 3 | Completed | Lesion in Body Region | 324 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03986138) |
| November 21, 2018 | NCT03749252 | Pharmacokinetics, Safety and Efficacy of P03277 in Pediatric Patients Undergoing Central Nervous System Contrast-enhanced MRI | Guerbet | Phase 2 | Completed | Central Nervous System Indication, Pediatric Patients, Body Indication | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03749252) |
| September 5, 2018 | NCT03657784 | Pharmacokinetics, Dialysability and Safety of P03277 in Healthy Volunteers and in Patients With Impaired Renal Function | Guerbet | Phase 1 | Completed | Renal Insufficiency, Healthy Volunteers | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03657784) |
| September 5, 2018 | NCT03657264 | Cardiac Safety Evaluation of P03277 | Guerbet | Phase 1 | Completed | Healthy Volunteers | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03657264) |
| July 27, 2018 | NCT03603106 | Pharmacokinetics, Pharmacodynamics Profile and Tolerance of P03277 in Healthy Subjects and Patients With Brain Lesions | Guerbet | Phase 1/2 | Completed | Healthy Volunteers, Brain Lesion | 142 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03603106) |
| February 9, 2017 | NCT03048006 | Post-marketing Surveillance Study for Evaluation of Dotarem Safety | Guerbet | Observational | Completed | Contrast-enhanced MRI With Dotarem | 44,456 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03048006) |
| February 2, 2017 | NCT03041298 | Post Marketing Surveillance Study for Evaluation of Efficacy and Safety of Dotarem in Magnetic Resonance Mammography | Guerbet | Observational | Completed | MR Mammography With Dotarem | 1,537 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03041298) |
| November 25, 2016 | NCT02973516 | Proof of Concept Study Concerning Efficacy of P03277 MR Imaging in HCC Diagnosis | Guerbet | Phase 2 | Completed | Chronic Liver Disease, HepatoCellular Carcinoma | 41 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02973516) |
| December 17, 2015 | NCT02633501 | P03277 Dose Finding Study in Central Nervous System (CNS) Magnetic Resonance Imaging (MRI) | Guerbet | Phase 2 | Completed | CNS Lesion, Blood Brain Barrier Defect | 312 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02633501) |
| December 9, 2015 | NCT02625389 | A Study to Evaluate How Safe and Effective is the Mixture of Lipiodol® Ultra Fluid and Glue When Used for Embolization Procedures | Guerbet | Phase 4 | Completed | Congenital Hemangioma, Hemangioendothelioma, Angiosarcoma, Arteriovenous Malformations | 132 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02625389) |
| April 8, 2015 | NCT02411201 | DOTAREM Pharmacokinetics and Safety Study in Pediatric Subjects Aged \< 2 Years | Guerbet | Phase 4 | Completed | Magnetic Resonance Imaging | 51 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02411201) |
| January 13, 2014 | NCT02034708 | Efficacy Evaluation of Dotarem®-Enhanced MRI Compared to Gadovist®/Gadavist®-Enhanced MRI in the Diagnosis of Brain Tumors | Guerbet | Phase 4 | Completed | Primary Brain Tumor | 279 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02034708) |
| March 7, 2013 | NCT01806740 | DCE-MRI Using Dotarem® in Evaluation of Therapeutic Response to Sorafenib in Patients With Advanced Stage HCC | Guerbet | Phase 4 | Terminated | Hepatocellular Carcinoma | 37 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01806740) |
| July 13, 2012 | NCT01639703 | Hepatic Xenetix-CT Perfusion | Guerbet | Phase 4 | Completed | Hepatocellular Carcinoma | 96 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01639703) |
| February 1, 2012 | NCT01523873 | Observational Post-marketing Study on the Safety and Efficacy of Dotarem® (SECURE Study) | Guerbet | Observational | Completed | General Safety Profile of DOTAREM | 35,921 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01523873) |
| November 8, 2011 | NCT01467271 | Observational Study on the Incidence of NSF in Renal Impaired Patients Following Dotarem Administration | Guerbet | Observational | Completed | Renal Insufficiency | 540 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01467271) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 4 |
| Phase 1/2 | 1 |
| Phase 2 | 4 |
| Phase 3 | 10 |
| Phase 4 | 16 |
| Observational | 7 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 33 |
| Terminated | 4 |
| Unknown | 2 |
| Recruiting | 2 |
| Withdrawn | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Renal Insufficiency | 5 |
| Carcinoma, Hepatocellular | 4 |
| Coronary Artery Disease | 2 |
| Cerebral Arterial Diseases | 2 |
| Central Nervous System Diseases | 2 |
| Peripheral Arterial Disease | 2 |
| Brain Neoplasms | 2 |
| Arterial Occlusive Diseases | 1 |
| Diabetes Mellitus, Type 2 | 1 |
| Pathologic Processes | 1 |
| Patient Participation | 1 |
| Nephrogenic Fibrosing Dermopathy | 1 |
| Neoplasms | 1 |
| Kidney Diseases | 1 |
| Breast Neoplasms | 1 |
| Prostatic Neoplasms | 1 |
| Colorectal Neoplasms | 1 |
| Neuroendocrine Tumors | 1 |
| Hemangioendothelioma | 1 |
| Hemangiosarcoma | 1 |
| Arteriovenous Malformations | 1 |
| Kidney Failure, Chronic | 1 |
| Renal Artery Obstruction | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Private equity firms in the United States](https://specstream.ai/data/businesses/private-equity-firms/united-states)
- [Shipping and delivery companies in the United States](https://specstream.ai/data/businesses/shipping-and-delivery-companies/united-states)
- [Tools wholesalers in the United States](https://specstream.ai/data/businesses/tools-wholesalers/united-states)
- [Women's health clinics in the United States](https://specstream.ai/data/businesses/womens-health-clinics/united-states)
- [B2B marketing consultants in the United States](https://specstream.ai/data/businesses/b2b-marketing-consultants/united-states)
- [Business financing companies in the United States](https://specstream.ai/data/businesses/business-financing-companies/united-states)
